Valbiotis Logo

Valbiotis

Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.

ALVAL | PA

Overview

Corporate Details

ISIN(s):
FR0013254851
LEI:
969500VP4JBJCF0MOP60
Country:
France
Address:
RUE PAUL VATINE, 17180 PERIGNY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Valbiotis is a research and development company committed to scientific innovation for the prevention and management of metabolic and cardiovascular diseases. The company specializes in developing and marketing plant-based, clinically tested dietary supplements and active substances. Its core focus is on major health risk factors including prediabetes, dyslipidemia, arterial hypertension, and metabolic liver diseases. Leveraging its botanical expertise, Valbiotis creates multi-target active substances that act on multiple physiological pathways. The company's product portfolio, including the ValbiotisPRO® range, is distributed through pharmacies and is aimed at both healthcare professionals and consumers seeking scientifically validated natural health solutions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-13 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 150.8 KB
2025-10-13 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-10-09 17:45
Earnings Release
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms…
English 298.7 KB
2025-10-09 17:45
ISS
VALBIOTIS SA: Valbiotis publie ses comptes semestriels et confirme sa feuille d…
French 306.2 KB
2025-10-09 17:45
Earnings Release
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms…
English 43.8 KB
2025-09-01 11:40
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-08-11 17:30
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 165.4 KB
2025-07-03 17:45
Regulatory News Service
VALBIOTIS SA: Bilan semestriel du contrat de liquidité
French 359.3 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 19.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue …
English 470.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le succès de son augmentation de capital de 6,9…
French 419.2 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its 6.9 million rights issue e…
English 142.5 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintai…
English 579.9 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le lancement d’une augmentation de capital avec…
French 511.1 KB

Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Valbiotis

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Valbiotis via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-01-17 N/A Other Other 10,400 46,072.00 EUR

Peer Companies

Company Country Ticker View
Global manufacturer of carbapenem antibiotic APIs for regulated markets.
South Korea 106190
HIKMA Pharmaceuticals PLC Logo
Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.
United Kingdom HIK
HISAMITSU PHARMACEUTICAL CO.,INC. Logo
A global leader in transdermal drug delivery systems for OTC and prescription pain relief.
Japan 4530
HLB Genex, Inc. Logo
Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.
South Korea 187420
HLB INC. Logo
A diversified group in pharma, shipbuilding, life sciences, and professional advisory services.
South Korea 028300
HLB Life Science CO.,LTD. Logo
Develops anti-cancer drugs and distributes IVD medical devices and lab supplies internationally.
South Korea 067630
HLB PANAGENE Co., LTD. Logo
A global leader in PNA technology for cancer diagnostics and precision medicine.
South Korea 046210
HLB Pep Co., Ltd. Logo
Develops and produces GMP peptides, APIs, and custom synthesis for the biopharma industry.
South Korea 196300
HLB PHARMACEUTICAL CO., LTD. Logo
Researches cancer drugs and offers pharmaceutical CMO and manufacturing services.
South Korea 047920
HLB SCIENCE Inc. Logo
Develops innovative therapeutics and diagnostics for infectious and neurodegenerative diseases.
South Korea 343090

Talk to a Data Expert

Have a question? We'll get back to you promptly.